文献速递临床试验与 GCP真实世界研究与卫生经济

舍曲林预防成人创伤性脑损伤后抑郁的临床与成本效果(STOP-D):多中心随机对照试验研究方案

The clinical and cost-effectiveness of sertraline in preventing depression in adults following a traumatic brain injury (STOP-D): study protocol for a multi-centre randomised controlled trial.
PubMed 文献 · Trials · 2025-10-27

STOP-D为多中心、双盲、安慰剂对照随机对照试验,计划招募514例伤后8周内、无当前重性抑郁障碍的成人创伤性脑损伤患者,随机接受舍曲林100 mg/日或安慰剂12个月,主要结局为12个月时患者健康问卷-9评估的抑郁症状严重度,并评估成本效果。

要点

  • 舍曲林100 mg/日或安慰剂治疗12个月,主要结局为12个月时患者健康问卷-9抑郁症状严重度。
  • 计划招募514例伤后8周内、无当前重性抑郁障碍的成人创伤性脑损伤患者。
  • 次要结局包括6、12、18个月时重性抑郁障碍发生率、精神共病、认知损害、物质使用、照护者负担、生产力与成本效果。

核心结论

  • 这是首个足够把握度的随机对照试验,探讨舍曲林作为创伤性脑损伤后抑郁预防干预的作用。
  • 研究结果将帮助判断创伤性脑损伤后尽早处方选择性5-羟色胺再摄取抑制剂是否可能降低抑郁风险并改善功能结局。

研究设计与样本

  • 多中心、双盲、安慰剂对照随机对照试验,计划招募514例参与者。
  • 纳入年龄≥18岁、伤后8周内可能的轻度或中重度创伤性脑损伤、且无当前重性抑郁障碍的成人。
  • 参与者随机接受舍曲林100 mg/日或安慰剂,疗程12个月。

主要发现

  • 主要结局为12个月时采用患者健康问卷-9测量的抑郁症状严重度。
  • 次要结局包括6、12、18个月时重性抑郁障碍发生率、精神共病、认知损害、物质使用、照护者负担、生产力与成本效果。

关键数值与推荐

  • 舍曲林剂量为100 mg/日,安慰剂对照,疗程12个月。
  • 主要结局评估时间点为12个月,采用患者健康问卷-9。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Traumatic brain injury (TBI) is a common presentation in emergency departments worldwide. Approximately 1.4 million adults present with TBI in England and Wales annually. Post-TBI depression (PTD) is a common neuropsychiatric consequence, affecting up to 50% of patients within two years, and is associated with adverse functional outcomes. PTD remains underdiagnosed and undertreated. Sertraline, a selective serotonin reuptake inhibitor (SSRI), has shown potential in reducing PTD incidence, yet evidence of its effectiveness in preventing depression from adequately powered trials is lacking. This randomised controlled trial aims to compare the clinical and cost-effectiveness of sertraline in reducing the risk of PTD in adults compared to usual care. METHODS: The design is a multi-centre, double-blind, placebo-controlled, randomised controlled trial (RCT) aiming to recruit 514 participants. Eligible adults (aged ≥ 18 years) with possible, mild or moderate-severe TBI within eight weeks of injury and without current major depressive disorder (MDD) are randomly assigned to receive sertraline (100 mg daily) or placebo for 12 months. The primary outcome is depressive symptom severity at 12 months, measured using the Patient Health Questionnaire-9. Secondary outcomes include incidence rates of major depressive disorder, psychiatric comorbidities, cognitive impairment, substance use, carer burden, productivity and cost-effectiveness at 6, 12 and 18 months. DISCUSSION: This is the first adequately powered RCT to investigate sertraline as a preventive intervention for PTD. Findings will help inform whether prescribing an SSRI soon after a TBI may reduce the risk of depression and improve functional outcomes. TRIAL REGISTRATION: This study is registered in the European Union Drug Regulating Authorities Clinical Trials Database (EudraCT no. 2022-000072-18, date: 7 January 2022) and the ISRCTN - The UK's Clinical Study Registry (ISRCTN no. 17518945, date: 23 December 2022, https://www.isrctn.com/ISRCTN17518945 ).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Burgess J, Ismail K, Raymont V, et al. The clinical and cost-effectiveness of sertraline in preventing depression in adults following a traumatic brain injury (STOP-D): study protocol for a multi-centre randomised controlled trial. Trials. 2025. PMID: 41146233. doi:10.1186/s13063-025-09027-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。